Takayama Hiroo, Landes Elissa, Truby Lauren, Fujita Kevin, Kirtane Ajay J, Mongero Linda, Yuzefpolskaya Melana, Colombo Paolo C, Jorde Ulrich P, Kurlansky Paul A, Takeda Koji, Naka Yoshifumi
Department of Surgery, Columbia University Medical Center, New York, NY.
Department of Surgery, Columbia University Medical Center, New York, NY.
J Thorac Cardiovasc Surg. 2015 May;149(5):1428-33. doi: 10.1016/j.jtcvs.2015.01.042. Epub 2015 Feb 7.
To facilitate venoarterial extracorporeal membrane oxygenation (ECMO) insertion for cardiogenic shock, we recently adopted a strategy of using a 15F arterial cannula in all patients, rather than 1 designed to maximize flow. We aimed to compare the clinical outcomes of these 2 strategies.
In this retrospective study, 101 consecutive patients supported with ECMO via femoral cannulation between March 2007 and March 2013 were divided into 2 groups: Group L (17F-24F arterial cannula to accommodate full flow [ie, cardiac index of 2.5 L/m(2)/min]; n = 51) and Group S (15F arterial cannula; n = 50). The primary outcomes of interest were patients' overall status at 24 hours of support and cannulation-related adverse events.
There were no significant differences in patient demographics, etiology of cardiogenic shock, or severity of illness before ECMO initiation between the 2 groups. Group L had significantly higher ECMO flow than Group S (flow index at 24 hours: 2.2 ± 0.7 vs 1.7 ± 0.3 L/m(2)/min; P < .001). However, there was no significant difference in use of vasoactive medication/hemodynamic parameters/laboratory parameters. Group L had higher incidence of cannulation-related adverse events (35% vs 22% in Group S [P = .14]), particularly in cannulation site bleeding (28% vs 10% [P = .03]). Thirty-day survival was 55% in Group L versus 52% in Group S (P = .77). Bleeding complication occurred in 53% in Group L versus 32% in Group S (P = .03).
Compared with the use of larger cannulas, ECMO with a 15F arterial cannula appears to provide comparable clinical support with reduced bleeding complications.
为便于对心源性休克患者进行静脉-动脉体外膜肺氧合(ECMO)插管,我们最近采用了一种策略,即对所有患者均使用15F动脉插管,而非旨在使流量最大化的插管。我们旨在比较这两种策略的临床结果。
在这项回顾性研究中,2007年3月至2013年3月期间通过股动脉插管接受ECMO支持的101例连续患者被分为两组:L组(使用17F - 24F动脉插管以适应全流量[即心脏指数为2.5L/m²/min];n = 51)和S组(使用15F动脉插管;n = 50)。主要关注的结局是患者在支持24小时时的总体状况以及与插管相关的不良事件。
两组患者在人口统计学、心源性休克病因或开始ECMO治疗前的疾病严重程度方面无显著差异。L组的ECMO流量显著高于S组(24小时时的流量指数:2.2±0.7 vs 1.7±0.3L/m²/min;P <.001)。然而,在血管活性药物的使用/血流动力学参数/实验室参数方面无显著差异。L组与插管相关的不良事件发生率较高(L组为35%,S组为22%[P = 0.14]),尤其是在插管部位出血方面(28% vs 10%[P = 0.03])。L组30天生存率为55%,S组为52%(P = 0.77)。L组出血并发症发生率为53%,S组为32%(P = 0.03)。
与使用较大插管相比,使用15F动脉插管的ECMO似乎能提供相当的临床支持,同时减少出血并发症。